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We conﬁ  rmed circulation of human metapneumovirus 
(HMPV) among children with febrile and respiratory illness 
in an urban slum in Dhaka, Bangladesh, during active sur-
veillance in 2001. HMPV was the most common single virus 
identiﬁ  ed among febrile children and appears to contribute 
to the high rates of illness in this population. 
H
uman metapneumovirus (HMPV) is the newest mem-
ber of the family Paramyxoviridae, in the subfam-
ily Pneumovirinae, shared with respiratory syncytial virus 
(RSV) (1). It appears to have 2 distinct genetic subgroups 
(2,3). HMPV was ﬁ  rst described in a population of chil-
dren in the Netherlands in 2001 (1) and has subsequently 
been linked with lower respiratory tract illness (LRTI) in 
children and adults (2,4). Although HMPV independently 
contributes to LRTI, some studies report more severe cases 
when HMPV is a coinfectant with RSV (5,6) or inﬂ  uenza 
(7); other studies have found no synergy (3). 
 The Study
As previously reported (8), we undertook fever surveil-
lance in Kamalapur, an urban community in Dhaka used by 
the International Center for Diarrheal Disease Research, 
Bangladesh (ICDDR,B) as a ﬁ  eld site since 1998. The site 
has 7 geographic strata and 379 clusters. We randomly 
selected clusters within strata and enrolled all households 
within those clusters for surveillance, after obtaining in-
formed written consent. 
Field research assistants (FRAs) screened for fever 
across all ages among 5,000 households once weekly using 
standardized calendar questionnaires. FRAs referred chil-
dren <13 years of age who reported fever for any duration, 
or anyone >13 years who reported fever for >3 days, to 
our onsite clinic where study physicians conducted stan-
dardized history and physical examinations. If an axillary 
temperature of >38°C was conﬁ  rmed, physicians collected 
3–5 mL of blood from children <5 years and persons >5 
years, respectively, as well as convalescent blood samples 
14 days later. Blood samples were allowed to clot and then 
centrifuged to obtain serum. 
We retrospectively selected serum samples to test for 
respiratory viruses from patients <13 years of age who had 
cough for 1–3 days and fever of >38.5°C; we also selected 
paired serum samples negative for dengue by immunoglob-
ulin M antibody capture (MAC)–ELISA.  These samples 
were sent to the Centers for Disease Control and Prevention 
(CDC; Atlanta, Georgia, USA) for testing by hemaggluti-
nation inhibition for inﬂ  uenza and enzyme immunoassay 
for RSV; parainﬂ  uenza types 1, 2, and 3; adenovirus; and 
HMPV by using standard methods (9,10). A positive acute 
HMPV infection was deﬁ  ned as a >4-fold rise in titer be-
tween acute-phase and convalescent-phase samples. 
Statistical analysis was performed by using StataSE 
Release 9.2 (StataCorp, College Station, TX, USA). We 
compared continuous variables between groups by using 
analysis of variance. For univariate analysis of categorical 
variables, we used 2 × 2 tables; for multivariate analysis, we 
used conditional logistic regression to determine strength 
of association between HMPV infection and potential ex-
planatory covariates to obtain relative odds (RO) and 95% 
conﬁ  dence intervals (CIs); p values were obtained by using 
the Fisher exact test. This study was approved by the re-
search review and ethical review committees of ICDDR,B 
and the Institutional Review Board of CDC. 
From December 6, 2000, through December 5, 2001, 
889 persons came to our clinic with fever, and blood samples 
were collected from 888 (99.9%). Of the 889, 775 (84.9%) 
were self-referred; 114 (93.4%) of 122 were referred by 
FRAs during the same period. Of the 888 sampled patients, 
we selected serum samples from 128 children <13 years 
of age who had paired samples, documented fever >38.5C, 
cough for 1–4 days before ﬁ  rst blood collection, and nega-
tive test results for dengue antibodies by MAC-ELISA. 
These samples were tested by hemagglutination inhibition 
against inﬂ  uenza virus A (H1N1 and H3N2) and inﬂ  uenza 
type B. Among these, 107 paired samples had sufﬁ  cient 
remaining serum to be tested for other respiratory viruses, 
including HMPV. 
Table 1 shows the distribution of all virus infections 
detected by serologic testing of 107 paired specimens. Of 
60 infections detected among these children, 20 (33.3%) 
were caused by HMPV, the largest single group after in-
ﬂ  uenza (although more than either inﬂ  uenza A or B alone). 
HMPV was detected in the dry premonsoon season from 
January through the end of June (Figure). 
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We found no demographic differences in subgroup 
analysis by age group (<5 years and >5 years) or between 
children with acute HMPV infection and noninfected chil-
dren (Table 2). Also, no differences were found in the re-
ported history of fever duration or other complaints asso-
ciated with febrile or respiratory illness in this population 
before treatment. 
Clinical  ﬁ   ndings (Table 2) showed no differences 
in mean fever or proportion of children with high fever 
(>39°C). However, compared with non-HMPV infection, 
acute HMPV infection was 3.5 times more likely (95% CI 
1.02–11.24) to be associated with clinical pneumonia in all 
children and 4.8 times more likely (95% CI 0.90–23.86) 
to be associated with altered mental status (irritability/leth-
argy) in children <5 years old (Table 2). Only 1 child with 
acute HMPV infection had coinfection with another virus 
(inﬂ  uenza A). 
Conclusions
To our knowledge, ours is the ﬁ  rst reported ﬁ  nding of 
HMPV in Bangladesh demonstrating substantial contribu-
tion of HMPV to febrile and lower respiratory tract illness 
in children <13 years of age. Our report substantiates that 
of a study from India (11). In a hospital study conducted in 
Bangladesh, a virus was isolated in only 33.3% of children 
with LRTI (12). Although HPMV was unknown at that time, 
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Table 1. Viruses detected in children <13 years of age by serology, Kamalampur, Bangladesh, December 2000–December 2001 
Virus No. infections  % (N = 60)  Cumulative % 
Human metapneumovirus  20 33.3 33.3
Respiratory syncytial virus  3 5.0 38.3
Adenovirus 4 6.7 45.0
Parainfluenza virus 3  9 15.0 60.0
Influenza (H1N1)  8 13.3 73.3
Influenza (H3N2)  2 3.3 76.6
Influenza B  14 23.3 99.9
Figure. Human metapneumovirus (HMPV) infection in children <13 
years of age, Kamalapur, Bangladesh, 2001.
Table 2. Demographic and clinical characteristics of children <13 years of age presenting with fever, Kamalampur, Bangladesh, 
December 2000–December 2001* 
Variables†
HMPV positive  
(N = 20) 
HMPV negative
(N = 87) 
Relative odds
(95% CI)  p value‡ 
Mean age, y§ (SD, 95% CI)  4.5 (2.6; 3.2–5.7)  4.5 (3.1; 3.9–5.2)  – 0.951
Mean age for 0–4 age range, y§ (SD, 95% CI)  2.9 (1.4; 2.1–3.8)  2.3 (1.2; 2.0–2.7)  – 0.113
Mean age for 5–12 age range, y§ (SD, 95% CI)  7.3 (1.9; 5.5–9.0)  7.7 (1.8; 7.1–8.4)  – 0.556
Children <5 y, no. (%)  13 (65.0)  52 (59.8)  1.25 (0.41–4.08)  0.801
Male gender, no. (%)  9 (45.0)  49 (56.3)  0.63 (0.21–1.89)  0.457
Duration of fever prior to clinic,§ d (SD, 95% CI)  3.1 (0.8; 2.7–3.5)  3.1 (1.7; 2.7–3.4)  – 0.983
Symptoms 
Headache, no. (%)  8 (40.0)  34 (39.1)  1.04 (0.33–3.10)  1.000
Body pain, no. (%)  4 (20.0)  25 (28.7)  0.62 (0.14–2.20)  0.580
Rhinorrhea, no. (%)  16 (80.0)  60 (69.0)  1.80 (0.51–8.06)  0.419
Difficulty breathing, no. (%)  3 (15.0)  4 (4.6)  3.66 (0.48–23.48)  0.119
Normal activity/behavior, no. (%)  15 (75.0)  64 (73.6)  0.73 (0.22–2.20)  0.620
Fever,§ °C (SD, 95% CI)  39.2 (0.6; 39.0–39.5)  39.1 (0.6; 39.0–39.2)  – 0.899
High fever (>39°C), no. (%)  10 (50.0)  49 (56.3)  0.78 (0.26–2.32)  0.627
Respiratory rate§ (SD, 95% CI)  42 (11; 36–47)  41 (9; 39–43)  – 0.808
Crepitations (rales) or wheezing, no. (%)  11 (55.0)  28 (32.1)  2.57 (0.85–7.86)  0.072
Altered mental status,¶ no. (%)  5 (25.0)  8 (9.2)  3.29 (0.73–13.19)  0.065
Altered mental status¶ if <5 y#, no. (%)  5 (38.5)  6 (11.5)  4.79 (0.90–23.86)  0.035
Pneumonia/LRTI diagnosis, no. (%)  8 (40.0%)  14 (16.1)  3.48 (1.02–11.24)  0.029
*HPMV, human metapneumovirus; CI, confidence interval; SD, standard deviation; LRTI, lower respiratory tract illness. 
†Categorical variables report N persons (percent of persons with characteristic in each group). Compared by 2 x 2 table, odds ratio with 95% CI.  
‡2-tailed Fisher exact text. 
§Continuous variables. Means compared by using Student t test. 
¶Irritability, lethargy. 
#N = 65 children <5 y. Metapneumovirus in Children, Bangladesh 
and thus would not have been reported, the contribution of 
viruses to LRTI in children is often underreported by stud-
ies that have focused on bacterial infection identiﬁ  cation or 
that did not include collection of paired serum samples to 
detect viral infections (3). HMPV has likely been a major 
factor in pneumonia and bronchiolitis in this population, as 
it has in others (1,2,11). In this study, HMPV was not only 
signiﬁ  cantly associated with pneumonia, but with lethargy, 
an indicator of severe pneumonia in young children. Given 
the high rates of illness and death from pneumonia in this 
population (8), this association has important implications 
for disease control strategies. HMPV was also found in the 
dry pre-Monsoon season, when incidence of pneumonia 
peaks in this population. Similarly, parainﬂ  uenza peaks 
from March–April. In contrast, inﬂ  uenza occurs before and 
during the Monsoon season (March–August). 
Our pilot study to assess the possible effects of HMPV 
on LRTI in children in Bangladesh had the following limi-
tations: 1) healthy control patients were not included in the 
study; 2) the study was not originally designed to look for 
respiratory viruses; 3) fever was a main selection criterion 
and may have biased selection of more severe illnesses (a 
previous pneumonia study indicated that <33% of children 
in this environment with severe pneumonia have fever (13), 
perhaps substantially underestimating HMPV prevalence); 
4) the observation period of 1 year may not represent the 
typical seasonal pattern; 5) case identiﬁ  cation was based 
on serologic test results, and some children may have had a 
subclinical immune response or acute-phase samples may 
have been collected too late to observe a signiﬁ  cant rise in 
titer, thus underestimating prevalence of disease; and 6) the 
study included insufﬁ  cient cases to analyze viral interac-
tion. To more clearly deﬁ  ne the role of HMPV and other 
respiratory viruses in this population, and to improve dis-
ease control strategies, fever surveillance targeting a broad-
er range of clinical syndromes over a sustained period is 
needed.  
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